Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial)

@article{Dbrowski2020ClinicalEO,
  title={Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial)},
  author={R. Dąbrowski and P. Syska and J. Mączyńska and M. Farkowski and Stefan Sawicki and A. Kubaszek-Kornatowska and P. Michałek and I. Kowalik and H. Szwed and T. Hryniewiecki},
  journal={Trials},
  year={2020},
  volume={21}
}
Background Atrial fibrillation (AF) is the most frequent cardiac arrhythmia which increases the risk of thromboembolic complications and impairs quality of life. An important part of a therapeutic approach for AF is sinus rhythm restoration. Antiarrhythmic agents used in pharmacological cardioversion have limited efficacy and potential risk of proarrhythmia. Simultaneously, underlying conditions of AF should be treated (e.g. electrolyte imbalance, increased blood pressure, neurohormonal… Expand
2 Citations
The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
TLDR
The novelty of this observation relies on the independent positive impact of canrenone on the all-cause mortality and clinical improvement of COVID-19 patients ranging from moderate to severe diseases. Expand
Design and analysis considerations for utilizing a mapping function in a small sample, sequential, multiple assignment, randomized trials with continuous outcomes.
TLDR
Rerandomization based on a mapping function of a continuous outcome allows for snSMART designs without requiring a binary outcome and results in more efficient treatment effect estimates and similar outcomes for trial patients. Expand

References

SHOWING 1-10 OF 25 REFERENCES
A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
TLDR
Vernakalant rapidly converted recent-onset AF to SR, was well tolerated, and may be a valuable therapeutic alternative for reestablishing SR in patients with recent-ONSet AF. Expand
Abstract 9533: Effect of Combined Ramipril-Canrenone on Atrial Fibrillation Recurrence in Hypertensive Patients With a History of Paroxysmal Atrial Fibrillation
TLDR
It is suggested that in patients with atrial fibrillation R/C combination is more effective than R/H combination in reducing AF recurrence as well as in improving PWD and cardiac fibrosis despite a similar BP reduction. Expand
Effect of combined spironolactone-β-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study).
TLDR
Combined spironolactone plus β-blocker treatment might be a simple and valuable option in preventing AF episodes in patients with normal left ventricular function and a history of refractory paroxysmal AF. Expand
Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.
  • I. Savelieva, N. Kakouros, A. Kourliouros, A. Camm
  • Medicine
  • Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2011
TLDR
This review provides a contemporary evidence-based insight into the role of upstream therapies in primary (Part I) and secondary (Part II) prevention of AF. Expand
Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention.
  • I. Savelieva, N. Kakouros, A. Kourliouros, A. Camm
  • Medicine
  • Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2011
Fundamental research into molecular mechanisms of atrial fibrillation (AF) and improved understanding of processes involved in the initiation and maintenance of AF have transformed the traditionalExpand
Vernakalant Hydrochloride for Rapid Conversion of Atrial Fibrillation: A Phase 3, Randomized, Placebo-Controlled Trial
TLDR
Vernakalant demonstrated rapid conversion of short-duration AF and was well tolerated and four vernakalants-related serious adverse events occurred in 3 patients. Expand
Increased Plasma Aldosterone during Atrial Fibrillation Declines following Cardioversion
TLDR
Restoration and maintenance of SR in patients with persistent AF significantly lowered the level of aldosterone up to 180 days after cardioversion, indicating activation of RAAS during AF. Expand
Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
TLDR
In conclusion, vernakalant demonstrated a rapid and high rate of conversion for short-duration AF and was well tolerated. Expand
Effect of ramipril/hydrochlorothiazide and ramipril/canrenone combination on atrial fibrillation recurrence in hypertensive type 2 diabetic patients with and without cardiac autonomic neuropathy
TLDR
It is suggested that in type 2 diabetic hypertensives, ramipril/canrenone treatment was more effective than ramiprill/HCTZ in reducing AF recurrence, which could be related to the greater improvement in cardiac fibrosis. Expand
Aldosterone Pathway Blockade to Prevent Atrial Fibrillation: A Systematic Review and Meta-Analysis.
TLDR
It is hypothesized that aldosterone pathway blockade with mineralocorticoid receptor antagonists (MRA) reduces atrial fibrosis, and thus AF, and can be considered an additive therapeutic strategy in AF. Expand
...
1
2
3
...